For the quarter ending 2025-09-30, INMB made $8,394K in revenue. -$6,473K in net income. Net profit margin of -77.11%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Impairment of acquired in-process research and development intangible assets | - | 16,514 | - | - |
| Revenue | - | 0 | 50 | 5 |
| General and administrative | 2,546 | 2,253 | 2,316 | 2,226 |
| Research and development | 4,887 | 5,804 | 7,639 | 8,023 |
| Total operating expenses | 7,433 | 24,571 | 9,955 | 10,249 |
| Loss from operations | -7,433 | -24,571 | -9,905 | -10,242 |
| Other income (expense), net | - | - | 166 | 120 |
| Other income, net | 961 | 113 | - | 120 |
| Net loss | -6,472 | -24,458 | -9,739 | -10,121 |
| Other comprehensive loss foreign currency translation | -1 | -153 | -35 | 296 |
| Total comprehensive loss | -6,473 | -24,611 | -9,774 | -9,826 |
| Net loss per common share basic (in dollars per share) | -0.24 | -1.05 | -0.43 | -0.505 |
| Net loss per common share diluted (in dollars per share) | -0.24 | -1.05 | -0.43 | -0.505 |
| Weighted average common shares outstanding basic (in shares) | 26,585,258 | 23,298,455 | 22,496,191 | -9,774,347.5 |
| Weighted average common shares outstanding diluted (in shares) | 26,585,258 | 23,298,455 | 22,496,191 | -9,774,347.5 |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)